Novartis: Decentralized trials could expand enterprise around the world

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/RomoloTavani)
(Image: Getty/RomoloTavani)
Novartis hopes to eventually recruit ‘a significant portion’ of patients into a decentralized clinical trial model that has the potential to increase the company’s reach globally, says exec.

Last week Novartis and Science 37 announced​ an expanded alliance through which the companies will launch up to 10 “decentralized” clinical trials across the US.

Decentralized trials shift some or all aspects of a clinical trial from a central site, such as a hospital, to the participant’s home or physician’s office.

“By bringing the trial to the patient, Novartis aims to decrease the burden of clinical trial participation on patients and trial centers,”​ Jake LaPorte, global head of digital development at Novartis told

The more flexible approach also could benefit underrepresented populations.

LaPorte said: “This approach also has the potential to increase the reach of our leading drug development and clinical trials enterprise into under-represented and underserved populations around the world, improving the caliber and quantity of data available to aid in drug discovery and development.”

Currently, Novartis is in the process of selecting specific indication and trials where it will deploy the decentralized approach, which leverages Science 37’s technology to enable patient participation using mobile devices and telemedicine services.

LaPorte said the characteristics of the target patient population, including size, will be defined after these decisions have been made.

The studies will use both decentralized and traditional models, “with the aspiration of attaining increasing degrees of decentralization towards a mostly ‘site-less’ model overtime,”​ he added.

Our aspiration, overtime, is to recruit a significant portion of patients into this decentralized model when deployed on a clinical trial.”

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more